BACKGROUND: Familial cylindromatosis is a rare genetic disorder, giving rise to neoplasms of the skin appendages. We have recently shown that loss of the cylindromatosis tumour suppressor gene leads to activation of NF-kappaB, a transcription factor having antiapoptotic activity. This provides a possible explanation for the deregulated growth of cylindromas. In cell-based assays, salicylate can prevent NF-kappaB activation caused by loss of the cylindromatosis gene, suggesting that salicylic acid application might be a potential treatment for cylindromatosis. OBJECTIVES: To assess the effectiveness of topical application of salicylic acid on familial cylindromas. METHODS: Cylindromas in five patients from four different cylindromatosis families were treated with twice daily and then once daily topical salicylic acid. Clinical response was determined by serial tumour measurements. RESULTS: In total 17 cylindromas in five patients were studied: 12 target lesions and five control lesions. The median size of the cylindromas was 1.0 cm (range, 0.6-2.8 cm). Two of the 12 cylindromas showed a complete remission. Another eight lesions showed some response, but not sufficient to qualify as partial remission. The control lesions remained stable or increased in size. CONCLUSIONS: Salicylic acid is a well-tolerated and potential new treatment for cylindromatosis.
BACKGROUND:Familial cylindromatosis is a rare genetic disorder, giving rise to neoplasms of the skin appendages. We have recently shown that loss of the cylindromatosis tumour suppressor gene leads to activation of NF-kappaB, a transcription factor having antiapoptotic activity. This provides a possible explanation for the deregulated growth of cylindromas. In cell-based assays, salicylate can prevent NF-kappaB activation caused by loss of the cylindromatosis gene, suggesting that salicylic acid application might be a potential treatment for cylindromatosis. OBJECTIVES: To assess the effectiveness of topical application of salicylic acid on familial cylindromas. METHODS:Cylindromas in five patients from four different cylindromatosis families were treated with twice daily and then once daily topical salicylic acid. Clinical response was determined by serial tumour measurements. RESULTS: In total 17 cylindromas in five patients were studied: 12 target lesions and five control lesions. The median size of the cylindromas was 1.0 cm (range, 0.6-2.8 cm). Two of the 12 cylindromas showed a complete remission. Another eight lesions showed some response, but not sufficient to qualify as partial remission. The control lesions remained stable or increased in size. CONCLUSIONS:Salicylic acid is a well-tolerated and potential new treatment for cylindromatosis.
Authors: André Castro Pinho; Miguel José Pinto Gouveia; Ana Rita Portelinha Gameiro; José Carlos Pereira Silva Cardoso; Maria Margaria Martins Gonçalo Journal: J Dermatol Case Rep Date: 2015-09-30
Authors: Seth J Goldenberg; Jeffrey L McDermott; Tauseef R Butt; Michael R Mattern; Benjamin Nicholson Journal: Biochem Soc Trans Date: 2008-10 Impact factor: 5.407
Authors: Justyna Sicinska; Adriana Rakowska; Joanna Czuwara-Ladykowska; Andrzej Mroz; Marcin Lipinski; Anna Nasierowska-Guttmejer; Jolanta Sikorska; Katarzyna Sklinda; Monika Slowinska; Elzbieta Kowalska-Oledzka; Irena Walecka; Jerzy Walecki; Lidia Rudnicka Journal: J Dermatol Case Rep Date: 2007-12-29
Authors: Paula Miliani de Marval; Shazia Lutfeali; Jane Y Jin; Benjamin Leshin; M Angelica Selim; Jennifer Y Zhang Journal: Cancer Prev Res (Phila) Date: 2011-04-08
Authors: Neil Rajan; James A A Langtry; Alan Ashworth; Catherine Roberts; Pam Chapman; John Burn; Alison H Trainer Journal: Arch Dermatol Date: 2009-11
Authors: N Rajan; R Elliott; O Clewes; A Mackay; J S Reis-Filho; J Burn; J Langtry; M Sieber-Blum; C J Lord; A Ashworth Journal: Oncogene Date: 2011-05-09 Impact factor: 9.867